Re: Risk of Recurrent Disease in HER2-Positive Patients
I think an important part of the discussion is the recognition that ER+ Her2+ patients need continual dual blockade, i.e., the system of one year of Herceptin and 5 years of endocrine therapy is not optimal. I was very uncomfortable continuing endocrine therapy w/o some corresponding anti-Her2 therapy.
Hopeful
|